Reponex Pharmaceuticals ApS is a small Danish pharmaceutical company dedicated to the development of new, effective treatments for diseases that have significant patient and social impact and for which current therapy is lacking or in need of improvement.
The diseases may be acute and life threatening, such as bacterial peritonitis, or chronic diseases that spoil the quality of life and may shorten it, such as inflammatory bowel diseases, or complications of chronic diseases such as the disabling non-healing skin ulcers in patients with diabetes or venous insufficiency. There is a continuing medical need to improve the treatment of these difficult conditions.
This means essentially finding a new use for an established drug. Characteristically, this entails using the drug for a different indication (i.e. for treating another disease) than it was initially developed for, with the advantage of opening up a new market …
This means changing the route of administering the drug to a new one that is appropriate for the new indication. Essentially it means that Reponex reformulates the active pharmaceutical ingredients to make them suitable for local administration …
This means combining different drugs that act on different aspects of the disease pathology to achieve an additive or even synergistic effect. At the same time, it is convenient for both the patient and the clinician not to have to apply several different …